Corbus Pharmaceuticals (NASDAQ:CRBP) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. Their research is geared towards discovering and developing drugs that target the endocannabinoid system, aiming to provide innovative treatments for conditions with significant unmet medical needs. Corbus's key projects include advanced clinical trials for treatments in diseases such as systemic sclerosis and dermatomyositis. The objective of the company is to leverage its expertise in drug development to bring new, effective therapies to market, improving the lives of patients worldwide. With a dedicated team and a passion for science, Corbus strives to make a lasting impact in the field of medicine through its research and development efforts.